Additionally, no significant differences in cardiovascular protection were found between the two therapies in patients with poorly controlled diabetes (HbA1c 8.0)
Through careful management and patient engagement, healthcare providers can maximize the therapeutic benefits of these medications, enhance patient quality of life, and achieve optimal outcomes in the treatment of diabetes, obesity, and hypothyroidism
Przy Semaglutide i Tirzepatide efekt ten jest minimalny lub ujemny (organizm po redukcji masy ciaa odwrotnie obnia wydatek energetyczny, znany adaptacyjny spadek termogeniczny)
Kiss N, Prado CM, Daly RM, Denehy L, Edbrooke L, Baguley BJ, Fraser SF, Khosravi A, Abbott G
Estimation of the Youden Index and its associated cutoff point